EP2029143B1 - Substituted 8-[6-amino-3-pyridyl]xanthines - Google Patents

Substituted 8-[6-amino-3-pyridyl]xanthines Download PDF

Info

Publication number
EP2029143B1
EP2029143B1 EP07796049.0A EP07796049A EP2029143B1 EP 2029143 B1 EP2029143 B1 EP 2029143B1 EP 07796049 A EP07796049 A EP 07796049A EP 2029143 B1 EP2029143 B1 EP 2029143B1
Authority
EP
European Patent Office
Prior art keywords
compound
meoh
pharmaceutically acceptable
acceptable salt
pyridyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP07796049.0A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2029143A2 (en
EP2029143A4 (en
Inventor
Guoquan Wang
Robert D. Thompson
Jayson M. Rieger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dogwood Pharmaceuticals Inc
Original Assignee
Dogwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dogwood Pharmaceuticals Inc filed Critical Dogwood Pharmaceuticals Inc
Priority to PL07796049T priority Critical patent/PL2029143T3/pl
Priority claimed from PCT/US2007/013849 external-priority patent/WO2007149277A2/en
Publication of EP2029143A2 publication Critical patent/EP2029143A2/en
Publication of EP2029143A4 publication Critical patent/EP2029143A4/en
Application granted granted Critical
Publication of EP2029143B1 publication Critical patent/EP2029143B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6

Definitions

  • the present invention relates to substituted 8-[6-amino-3-pyridyl]xanthines and pharmaceutical compositions that are selective antagonists of A 2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
  • its use is associated with unpleasant side effects, such as insomnia and diuresis.
  • the use of theophylline as a bronchodilator, for relief of asthma has been supplanted by drugs of other classes, e.g., selective ⁇ 2 -adrenergic agonists, corticosteroids, and recently leukotriene antagonists. These compounds also have limitations. Thus, the development of a theophylline-like drug with reduced side effects is still desirable.
  • Adenosine activates four subtypes of G protein-coupled adenosine receptors (ARs), A 1 A 2A /A 2B /A 3 .
  • Enprofylline (below) is another example of a xanthine that has been reported to block A 2B adenosine receptors and is used to treat asthma. It has also been shown by LaNoue et al (U.S. Patent No. 6,060,481 ) that selective adenosine A 2B antagonists are useful for improving insulin sensitivity in a patient.
  • a 2B ARs are expressed in some mast cells, such as the BR line of canine mastocytoma cells, which appear to be responsible for triggering acute Ca 2+ mobilization and degranulation. (See Auchampach, J.A., et al., Mol. Pharmacol. 1997, 52, 846-860 and Forsyth, P., et al., Inflamm. Res. 1999, 48, 301-307 ).
  • a 2B ARs also trigger Ca 2+ mobilization, and participate in a delayed IL8 release from human HMC-1 mast cells.
  • a 2B AR functions associated with the A 2B AR are the control of cell growth and gene expression, (See Neary, J., et al., Trends Neurosci. 1996; 19, 13-18 ) endothelial-dependent vasodilation (See Martin, P.L., et al., J. Pharmacol. Exp. Ther. 1993, 265, 248-253 ), and fluid secretion from intestinal epithelia. (See Strohmeier, G.R., et al., J. Biol. Chem. 1995, 270, 2387-2394 ). Adenosine acting throukh A 2B ARs has also been reported to stimulate chloride permeability in cells expressing the cystic fibrosis transport regulator. (See Clancy, J.P., et al., Am. J. Physiol. 1999, 276, C361-C369 .)
  • Adenosine receptor subtype-selective probes are available for the A 1 , A 2A , and A 3 ARs, only few selective antagonists are known for the A 2B receptor. Therefore a continuing need exists for compounds that are selective A 2B receptor antagonists.
  • the present invention provides substituted 8-[6-amino-3-pyridyl]xanthines or stereoisomers or pharmaceutically acceptable salts that act as antagonists of A 2B adenosine receptors.
  • the invention also provides pharmaceutical compositions comprising a compound of the present invention or stereoisomer or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable excipient.
  • the invention provides a compound of the present invention or stereoisomer or a pharmaceutically acceptable salt thereof for use in a therapeutic method for treating a pathological condition or symptom in a mammal, such as a human, wherein the activity, e.g. over activity, of adenosine A 2B receptors is implicated in one or more symptoms of the pathology and antagonism (i.e. blocking) is desired to ameliorate such symptoms.
  • adenosine A 2B receptors is implicated in one or more symptoms of the pathology and antagonism (i.e. blocking) is desired to ameliorate such symptoms.
  • the present invention provides a compound or stereoisomer of a pharmaceutically acceptable salt thereof for use in a method of treating a disease comprising administering a therapeutically effective amount of at least one compound of the present invention or a stereoisomer of pharmaceutically acceptable salt thereof, wherein the disease is selected from asthma, allergies, allergic diseases (e.g. allergic rhinitis and sinusitis), autoimmune; diseases (e.g., lupus), diarrheal diseases, insulin resistance, diabetes (e.g., Type I and Type II), prevention of mast cell degranulation associated with ischemia/reperfusion injuries, heart attack, inhibition of angiogenesis in neoplastic tissues, and inhibition of angiogenesis in diabetic retinopathy or hyperbaric oxygen - induced retinopathy.
  • the disease is selected from asthma, allergies, allergic diseases (e.g. allergic rhinitis and sinusitis), autoimmune; diseases (e.g., lupus), diarrheal diseases, insulin resistance, diabetes (e.g., Type I and Type II), prevention
  • the invention provides a novel compound of the present invention for use in medical therapy.
  • the invention also provides the use of a novel compound of the present invention for the manufacture of a medicament for the treatment of a pathological condition or symptom in a mammal, which is associated with deleterious A 2B receptor activation or activity.
  • a method comprising contacting a compound of the present invention, optionally having a radioactive isotope (radionuclide), such as, for example, tritium, radioactive iodine (e.g., 125 I for binding assays for 123 I for Spectral Imaging) and the like, with target A 2B adenosine receptor sites comprising said receptors, in vivo or in vitro, so as to bind to said receptors.
  • a radioactive isotope such as, for example, tritium, radioactive iodine (e.g., 125 I for binding assays for 123 I for Spectral Imaging) and the like
  • Cell membranes comprising bound A 2B adenosine receptor sites can be used to measure the selectivity of test compounds for adenosine receptor subtypes or can be used as a tool to identify potential therapeutic agents for the treatment of diseases or conditions associated with A 2B -receptor mediation, by contacting said agents with said radioligands and receptors, and measuring the extent of the displacement of the radioligand and/or binding of the agent.
  • a compound selected from: or a stereoisomer or pharmaceutically acceptable salt thereof is provided.
  • a pharmaceutical composition comprising: (a) a therapeutically effective amount of a compound described above; and (b) a pharmaceutically acceptable excipient.
  • a compound of the present invention for use in preventing or treating a pathological condition or symptom in a mammal, wherein the activity of adenosine A 2B receptors is implicated and antagonism of its action is desired.
  • a compound of the present invention or a stereoisomer or pharmaceutically acceptable salt thereof for use in treating a disease wherein the disease is selected from asthma, allergies, allergic diseases (e.g., allergic rhinitis and sinusitis), autoimmune diseases (e.g., lupus), diarrheal diseases, insulin resistance, diabetes, prevention of mast cell degranulation associated with ischemia/reperfusion injuries, heart attack, inhibition of angiogenesis in neoplastic tissues, and inhibition of angiogenesis in diabetic retinopathy or hyperbaric oxygen-induced retinopathy.
  • the compound of the present invention for use in medical therapy.
  • a compound of the invention for the manufacture of a medicament useful for the treatment of a disease in a mammal.
  • the imidazole ring of the compounds of the present invention may exist in tautomeric forms or as tautomers, and thus are also included within the scope of the invention.
  • the tautomeric isomers are represented as the structures (Ia) and (Ib): wherein R, R 1 , R 2 , X and Z are defined herein.
  • Mammal and patient covers warm blooded mammals that are typically under medical care (e.g., humans and domesticated animals). Examples of mammals include (a) feline, canine, equine, bovine, and human and (b) human.
  • Treating covers the treatment of a disease-state in a mammal, and includes: (a) preventing the disease-state from occurring in a mammal, in particular, when such mammal is predisposed to the disease-state but has not yet been diagnosed as having it; (b) inhibiting the disease-state, e.g., arresting it development; (c) relieving the disease-state, e.g., causing regression of the disease state until a desired endpoint is reached; and/or (d) eliminating the disease-state, e.g., causing cessation of the disease state and/or its effects. Treating also includes the amelioration of a symptom of a disease (e.g., lessen the pain or discomfort), wherein such amelioration may or may not be directly affecting the disease (e.g., cause, transmission, expression, etc.).
  • a symptom of a disease e.g., lessen the pain or discomfort
  • “Pharmaceutically acceptable salts” refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines, alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quarternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include, but are not limited to, those derived from inorganic and organic acids selected from 1,2-ethanedisulfonic, 2-acetoxybenzoic, 2-hydroxyethanesulfonic, acetic, ascorbic, benzenesulfonic, benzoic, bicarbonic, carbonic, citric, edetic, ethane disulfonic, ethane sulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic, glycollyarsanilic, hexylresorcinic, hydrabamic, hydrobromic, hydrochloric, hydroiodide, hydroxymaleic, hydroxynaphthoic, isethionic, lactic, lactobionic, lauryl sulfonic, maleic, malic, mandelic, methanesulfonic, napsylic, nitric, oxalic, pamoic, pantothenic,
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 18th ed., Mack publishing Company, Easton, PA, 1990, p1445 .
  • “Therapeutically effect amount” includes an amount of a compound of the present invention that is effective when administered alone or in combination to treat an indication listed herein.
  • “Therapeutically effective amount” also includes an amount of the combination of compounds claimed that is effective to treat the desired indication.
  • the combination of compounds is preferably a synergistic combination. Synergy, as described, for example, by Chou and Talalay, Adv. Enzyme Regul. 1984, 22:27-55 , occurs when the effect of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent. In general, a synergistic effect is most clearly demonstrated at sub-optimal concentrations of the compounds. Synergy can be in terms of lower cytotoxicity, increased effect, or some other beneficial effect of the combination compared with the individual components.
  • the compounds of the present invention can be prepared by the methods described in US2005/0065341 .
  • the compounds of the present invention can also be prepared by the methods described in P.J. Scammells, et al., J. Med. Chem. 37, 2704-2712 (1994 ).
  • a diamino-1,3-disubstituted uracil is acylated with 6-chloronicotinoyl chloride in pyridine at 5°C to provide the compounds of Formula (5a).
  • the resulting amide (5a) is cyclized by refluxing in an aqueous sodium hydroxide solution to provide the compound A.
  • 6-Chloronicotinoyl chloride is prepared by refluxing 6-hydroxynicotinic acid in thionyl chloride using DMF as the catalyst as shown in Reaction Scheme 1.
  • Compound A can be alkylated with alkyl bromide or iodide to provide compounds of Formula A 1 .
  • Compounds A or A 1 react with substituted amine at 150-160°C in a pressure tube to give compounds of Formula B or B 1 .
  • Compounds of Formula B 1 where R 4 is hydrogen can react with acyl chloride to afford compounds where R 4 is -C(O)R 6 (C).
  • the compounds of the present invention can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, e.g ., orally or parenterally, by intravenous, intramuscular, topical, inhalation or subcutaneous routes.
  • a mammalian host such as a human patient
  • routes of administration e.g ., orally or parenterally
  • intravenous, intramuscular, topical, inhalation or subcutaneous routes e.g ., orally or parenterally
  • Exemplary pharmaceutical compositions are disclosed in " Remington: The Science and Practice of Pharmacy", A. Gennaro, ed., 20th edition, Lippincott, Williams & Wilkins, Philadelphia, PA .
  • the present compounds may be systemically administered, e.g ., orally, in combination with a pharmaceutically acceptable excipient such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets or may be incorporated directly with the food of the patient's diet.
  • a pharmaceutically acceptable excipient such as an inert diluent or an assimilable edible carrier.
  • the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules; elixirs, suspensions, syrups, wafers, and the like.
  • Such compositions and preparations should contain at least 0.1% of active compound.
  • the percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form.
  • the amount of active compound in such therapeutically useful compositions is such that an effective dosage level
  • the tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen or cherry flavoring may be added.
  • a liquid carrier such as a vegetable oil or a polyethylene glycol.
  • any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed.
  • the active compound may be incorporated into sustained-release preparations and devices.
  • the active compound may also be administered intravenously or intraperitoneally by infusion or injection.
  • Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes.
  • the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage.
  • the liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization.
  • the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
  • the present compounds may be applied in pure form, i.e ., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.
  • Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like.
  • Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants.
  • Adjuvants such as fragrances and additional antimicrobial agents can be added to' optimize the properties for a given use.
  • the resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings or sprayed onto the affected area using pump-type or aerosol sprayers.
  • Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.
  • useful dermatological compositions which can be used to deliver the compounds of the present invention to the skin are known to the art; for example, see Jacquet, et al. (U.S. Pat. No. 4,608,392 ), Geria (U.S. Pat. No. 4,992,478 ), Smith et al. (U.S. Pat. No. 4,559,157 ) and Wortzman (U.S. Pat. No. 4,820,508 ).
  • Useful dosages of the compounds of the present invention can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Patent. No. 4,93 8,949 .
  • the concentration of the compound(s) of the present invention in a liquid composition will be from (a) about 0.1-25 wt% and (b) about 0.5-10 wt%.
  • concentration in a semi-solid or solid composition such as a gel or a powder will be (a) about 0.1-5 wt% and (b) about 0.5-2.5 wt%.
  • a suitable dose will be in the range of from (a) about 1.0-100 mg/kg of body weight per day, (b) about 10-75 mg/kg of body weight per day, and (c) about 5-20 mg per kilogram body weight per day.
  • the compound can be conveniently administered in unit dosage form; e.g., tablets, caplets, etc., containing (a) about 4-400mg, (b) about 10-200 mg, and (c) about 20-100 mg of active ingredient per unit dosage form.
  • the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from (a) about 0.02-20 ⁇ M, (b) about 0.1-10 ⁇ M, and (c) about 0.5-5 ⁇ M. These concentrations may be achieved, for example, by the intravenous injection of a 0.005-0.5% solution of the active ingredient, or orally administered as a bolus containing about 4-400 mg of the active ingredient.
  • the compounds of the invention can also be administered by inhalation from an inhaler, insufflator, atomizer or pressurized pack or other means of delivering an aerosol spray.
  • Pressurized packs may comprise a suitable propellant such as carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a value to deliver a metered amount.
  • the desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example as two, three, four or more sub-doses per day.
  • the sub-dose itself may be further divided e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.
  • a 2B adenosine receptor antagonists The ability of compounds of the invention to act as an A 2B adenosine receptor antagonists may be determined using pharmacological models which are well known to the art or using test procedures described below.
  • the rat A 2B receptor cDNA was subcloned into the expression plasmid pDoubleTrouble using techniques described in Robeva, A. et al., Biochem. Pharmacol., 51, 545-555 (1996 ).
  • the plasmid was amplified in competent JM109 cells and plasmid DNA isolated using Wizard Megaprep columns (Promega Corporation, Madison, WI).
  • a 2B adenosine receptors were introduced into HEK-293 cells by means of Lipofectin as described in Felgner, P.L. et al., Proc. Natl. Acad. Sci. USA, 84 7413-7417 (1987 ).
  • Transfected HEK cells were grown under 5% CO 2 /95% O 2 humidified atmosphere at a temperature of 37°C. Colonies were selected by growth of cells in 0.6 mg/mL G418. Transfected cells were maintained in DMEM supplemented with Hams F12 nutrient mixture (1/1), 10% newborn calf serum, 2 mM glutamine and containing 50 IU/mL penicillin, 50 mg/mL streptomycin, and 0.2 mg/mL Geneticin (G418, Boehringer Mannheim). Cells were cultured in 10cm diameter round plates and subcultured when grown confluent (approximately after 72 hours).
  • Confluent monolayers of HEK-A 2B cells were washed with PBS followed by ice cold Buffer A (10 mM HEPES, 10 mM EDTA, pH 7.4) with protease inhibitors (10 ⁇ g/mL benzamidine, 100 ⁇ M phenylmethanesulfonyl fluoride, and 2 ⁇ g/mL of each aprotinin, pepstatin and leupeptin).
  • Buffer A 10 mM HEPES, 10 mM EDTA, pH 7.4
  • protease inhibitors 10 ⁇ g/mL benzamidine, 100 ⁇ M phenylmethanesulfonyl fluoride, and 2 ⁇ g/mL of each aprotinin, pepstatin and leupeptin.
  • the cells were homogenized in a Polytron (Brinkmann) for 20 s, centrifuged at 30,000 x g, and the pellets washed twice with buffer HE (10 mM HEPES, 1 mM EDTA, pH 7.4 with protease inhibitors). The final pellet was resuspended in buffer HE, supplemented with 10% sucrose and frozen in aliquots at -80 °C.
  • buffer HE 10 mM HEPES, 1 mM EDTA, pH 7.4 with protease inhibitors
  • the final pellet was resuspended in buffer HE, supplemented with 10% sucrose and frozen in aliquots at -80 °C.
  • membranes were thawed and diluted 5-10 fold with HE to a final protein concentration of approximately 1 mg/mL. To determine protein concentrations, membranes, and bovine serum albumin standards were dissolved in 0.2% NaOH/0.01% SDS and protein determined using fluorescamine fluorescence. Sto
  • Membranes were filtered on Whatman GF/C filters using a Brandel cell harvester (Gaithersburg, MD) and washed 3 times over 15-20 seconds with ice cold buffer (10 mM Tris, 1 mM MgCl 2 , pH 7.4).
  • B max and K D values were calculated by Marquardt's nonlinear least squares interpolation for single a site binding models. Marquardt, D. M., J. Soc. Indust. Appl. Math., 11, 431-441.21 (1963 ).
  • K i values for different compounds were derived from IC 50 values as described. Linden, J., J. Cycl. Nucl. Res., 8, 163-172 (1982 ). Data from replicate experiments are tabulated as means ⁇ SEM.
  • HEK-A 2B cells from one confluent T75 flask were rinsed with Ca 2+ and Mg 2+ -free Dulbecco's phosphate buffered saline (PBS) and then incubated in Ca 2+ and Mg 2+ -free HBSS with 0.05% trypsin and 0.53 mM EDTA until the cells detached.
  • PBS Ca 2+ and Mg 2+ -free Dulbecco's phosphate buffered saline
  • the cells were rinsed twice by centrifugation at' 250 x g in PBS and resuspended in 10 mL of HBSS composed of 137 mM NaCI, 5 mM KCl, 0.9 mM MgSO 4 , 1.4 mM CaCl 2 , 3 mM NaHCO 3 , 0.6 mM Na 2 HPO 4 , 0.4 mM KH 3 PO 4 , 5.6 mM glucose, and 10 mM HEPES, pH 7.4 and the Ca 2+ -sensitive fluorescent dye indo-1-AM (5 ⁇ M) 37 °C for 60 min.
  • HBSS composed of 137 mM NaCI, 5 mM KCl, 0.9 mM MgSO 4 , 1.4 mM CaCl 2 , 3 mM NaHCO 3 , 0.6 mM Na 2 HPO 4 , 0.4 mM KH 3 PO 4 , 5.6 mM glucose, and 10 mM HEPES,
  • the cells were rinsed once and resuspended in 25 mL dye-free HBSS supplemented with 1 U/ml adenosine deaminase and held at room temperature.
  • Adenosine receptor antagonists prepared as 100X stocks in DMSO or vehicle was added and the cells and transferred to a 37 °C bath for 2 minutes. Then the cells (1 million in 2 ml) were transferred to a stirred cuvette maintained at 37 °C within an Aminco SLM 8000 spectrofluorometer (SML instruments, Urbana IL). The ratios of indo-1 fluorescence obtained at 400 and 485 nm (excitation, 332 nm) was recorded using a slit width of 4 nm. NECA was added after a 100 s equilibration period.
  • Cyclic AMP generation was performed in DMEM/HEPES buffer (DMEM containing 50 mM HEPES, pH 7.4, 37 °C). Each well of cells was washed twice with DMEM/HEPES buffer, and then 100 ⁇ L adenosine deaminase (final concentration 10 IU/mL) and 100 ⁇ L of solutions of rolipram and cilostamide (each at a final concentration of 10 ⁇ M) were added, followed by 50 ⁇ L of the test compound (appropriate concentration) or buffer. After 15 minutes, incubation at 37 °C was terminated by removing the medium and adding 200 ⁇ L of 0.1 M HCl. Acid extracts were stored at -20 °C until assay.
  • cyclic AMP were determined following a protocol which utilized a cAMP binding protein (PKA) [van der Wenden et al., 1995], with the following minor modifications.
  • the assay buffer consisted of 150 mM K 2 HPO 4 /10 mM EDTA/ 0.2% BSA FV at pH 7.5. Samples (20 mL) were incubated for 90 minutes at 0 °C. Incubates were filtered over GF/C class microfiber filters in a Brandel M-24 Cell Harvester: The filters were additionally rinsed with 4 times 2 mL 150 mM K 2 HPO 4 /10 mM EDTA (pH 7.5, 4 °C). Punched filters were counted in Packard Emulsifier Safe scintillation fluid after 2 hours of extraction.
  • PKA cAMP binding protein
  • Proton nuclear magnetic resonance spectroscopy was performed on a Varian-300 MHz spectrometer and spectra were taken in DMSO- d 6 . Unless noted, chemical shifts are expressed as ppm downfield from relative ppm from DMSO (2.5 ppm).
  • Electro-spray-ionization (ESI) mass spectrometry was performed with a ThermoFinnigan LCQ mass spectrometer.
  • 6-Chloronicotinoyl chloride prepared from 6-hydroxynicotinic acid (1.444g, 10.4 mmol), in CH 2 Cl 2 (20 mL) was added dropwise to a solution of 5,6-diamino-1,3-disubstituteduracil (8 mmol) in dry pyridine (8.2 mL) maintained at 5°C.
  • the reaction was warmed to room temperature and stirred for an additional 3 hours. Water (50 mL) was added to quench the reaction. The solvent was evaporated to afford a dark colored oil.
  • the oil was refluxed for 2h in 2N NaOH (20 mL). After cooling, the pH was carefully adjusted to 7 with concentrated HCl. A solid formed and was collected and washed with water (20 mL), ether (20 mL) and chloroform (20 mL) to provide an off-white solid. The product was used in the next step without further purification.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP07796049.0A 2006-06-16 2007-06-13 Substituted 8-[6-amino-3-pyridyl]xanthines Active EP2029143B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL07796049T PL2029143T3 (pl) 2006-06-16 2007-06-13 Podstawione 8-[6-amino-3-pirydylo]ksantyny

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80503006P 2006-06-16 2006-06-16
US80556406P 2006-06-22 2006-06-22
US11/811,823 US7884100B2 (en) 2006-06-16 2007-06-12 Substituted 8-[6-amino-3-pyridyl]xanthines
PCT/US2007/013849 WO2007149277A2 (en) 2006-06-16 2007-06-13 Substituted 8-[6-amino-3-pyridyl]xanthines

Publications (3)

Publication Number Publication Date
EP2029143A2 EP2029143A2 (en) 2009-03-04
EP2029143A4 EP2029143A4 (en) 2009-07-15
EP2029143B1 true EP2029143B1 (en) 2015-07-08

Family

ID=56290980

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07796049.0A Active EP2029143B1 (en) 2006-06-16 2007-06-13 Substituted 8-[6-amino-3-pyridyl]xanthines

Country Status (18)

Country Link
US (2) US7884100B2 (ko)
EP (1) EP2029143B1 (ko)
JP (1) JP5417558B2 (ko)
KR (1) KR101413404B1 (ko)
CN (1) CN103145712A (ko)
AU (1) AU2007261568B2 (ko)
BR (1) BRPI0712001B8 (ko)
CA (1) CA2655598C (ko)
DK (1) DK2029143T3 (ko)
EA (1) EA016791B1 (ko)
ES (1) ES2548437T3 (ko)
HU (1) HUE026457T2 (ko)
IL (1) IL195916A (ko)
MX (1) MX2008015954A (ko)
MY (1) MY152178A (ko)
NZ (1) NZ597222A (ko)
PL (1) PL2029143T3 (ko)
PT (1) PT2029143E (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
EP2295434B1 (en) * 2003-08-25 2015-09-30 Dogwood Pharmaceuticals, Inc. Substituted 8-heteroaryl xanthines
US7618962B2 (en) * 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
WO2006091936A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
WO2006091897A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
US7884100B2 (en) 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
WO2022246392A1 (en) * 2021-05-18 2022-11-24 Purnovate, Inc. Cyclic amide-containing pyridyl xanthines as a 2b antagonists

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6060481A (en) 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
MXPA02007761A (es) * 2000-02-17 2002-10-11 Cv Therapeutics Inc Metodo para identificar y utilizar antagonistas del receptor a2b de adenosina para mediar la proliferacion celular en mamiferos.
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
HU229504B1 (hu) 2001-11-09 2014-01-28 Gilead Sciences A2B-adenozinreceptor-antagonisták
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
CA2443023A1 (en) 2002-02-01 2003-08-07 King Pharmaceuticals Research And Development, Inc. 8-heteroaryl xanthine adenosine a2b receptor antagonists
US7034070B2 (en) * 2002-09-27 2006-04-25 Vincent Chuang Arylalkyl aminofunctional silanes for epoxy laminates
US7148229B2 (en) 2003-02-19 2006-12-12 Hoffman-La Roche Inc. Sulfonamide substituted xanthine derivatives
EP2295434B1 (en) * 2003-08-25 2015-09-30 Dogwood Pharmaceuticals, Inc. Substituted 8-heteroaryl xanthines
WO2006028810A2 (en) 2004-09-01 2006-03-16 Cv Therapeutics, Inc. Method of wound healing using a2b adenosine receptor antagonists
US20060053029A1 (en) 2004-09-03 2006-03-09 Butler Keith R Methods and systems for providing an enterprise supply management portal
CA2583986A1 (en) 2004-10-15 2006-04-27 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists
WO2006091936A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7618962B2 (en) 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
WO2006091897A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Derivatives of 8-substituted xanthines
US7601723B2 (en) * 2005-02-25 2009-10-13 Pgx Health, Llc Pyridyl substituted xanthines
CA2612344A1 (en) 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
RU2457842C2 (ru) * 2006-03-17 2012-08-10 Гайлид Пало Альто, Инк. Способ предотвращения и лечения болезни печени с использованием антагонистов рецептора аденозина a2b
CA2652858A1 (en) * 2006-06-15 2007-12-27 Targeted Genetics Corporation Methods for treating target joints in inflammatory arthritis using aav vectors encoding a tnf antagonist
US7884100B2 (en) 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US7767685B2 (en) 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
US7875608B2 (en) * 2007-12-17 2011-01-25 Thompson Robert D Substituted 8-[6-amino-3pyridyl]xanthines
CA2718983C (en) 2008-03-26 2015-12-08 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist

Also Published As

Publication number Publication date
US20080004292A1 (en) 2008-01-03
AU2007261568B2 (en) 2013-05-16
HUE026457T2 (en) 2016-05-30
IL195916A0 (en) 2009-09-01
KR20090029268A (ko) 2009-03-20
PT2029143E (pt) 2015-10-20
CN103145712A (zh) 2013-06-12
MY152178A (en) 2014-08-15
CA2655598C (en) 2014-10-28
NZ597222A (en) 2013-06-28
US7884100B2 (en) 2011-02-08
US8258142B2 (en) 2012-09-04
EA200900010A1 (ru) 2009-10-30
EA016791B1 (ru) 2012-07-30
JP5417558B2 (ja) 2014-02-19
MX2008015954A (es) 2009-03-06
US20110082139A1 (en) 2011-04-07
PL2029143T3 (pl) 2015-12-31
IL195916A (en) 2015-06-30
EP2029143A2 (en) 2009-03-04
JP2010500284A (ja) 2010-01-07
ES2548437T3 (es) 2015-10-16
BRPI0712001A2 (pt) 2012-01-10
DK2029143T3 (en) 2015-09-21
KR101413404B1 (ko) 2014-06-27
BRPI0712001B1 (pt) 2020-04-07
AU2007261568A1 (en) 2007-12-27
EP2029143A4 (en) 2009-07-15
BRPI0712001B8 (pt) 2021-05-25
CA2655598A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
EP2295434B1 (en) Substituted 8-heteroaryl xanthines
US7601723B2 (en) Pyridyl substituted xanthines
US8258142B2 (en) Substituted 8-[6-amino-3-pyridyl]xanthines
US8153628B2 (en) Pyrazolyl substituted xanthines
US7875608B2 (en) Substituted 8-[6-amino-3pyridyl]xanthines
WO2006091897A2 (en) Derivatives of 8-substituted xanthines
US8349848B2 (en) Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors
WO2011005871A1 (en) Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists
WO2007149277A2 (en) Substituted 8-[6-amino-3-pyridyl]xanthines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081204

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20090612

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/497 20060101AFI20081203BHEP

Ipc: A61P 9/10 20060101ALI20090605BHEP

Ipc: C07D 473/06 20060101ALI20090605BHEP

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20091112

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TROVIS PHARMACEUTICALS LLC

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DOGWOOD PHARMACEUTICALS, INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150122

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 734837

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150715

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: FIAMMENGHI-FIAMMENGHI, CH

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007042068

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20150917

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2548437

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20151016

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20150925

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20150401921

Country of ref document: GR

Effective date: 20151022

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151108

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007042068

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E026457

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

26N No opposition filed

Effective date: 20160411

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 734837

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150708

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

REG Reference to a national code

Ref country code: LU

Ref legal event code: HC

Owner name: ALLERGAN SALES, INC.; US

Free format text: FORMER OWNER: ALLERGAN SALES, INC.

Effective date: 20200403

Ref country code: LU

Ref legal event code: PD

Owner name: ALLERGAN SALES, INC.; US

Free format text: FORMER OWNER: DOGWOOD PHARMACEUTICALS INC.

Effective date: 20200403

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602007042068

Country of ref document: DE

Representative=s name: ZIMMERMANN & PARTNER PATENTANWAELTE MBB, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602007042068

Country of ref document: DE

Owner name: ALLERGAN SALES, LLC, MADISON, US

Free format text: FORMER OWNER: DOGWOOD PHARMACEUTICALS, INC., CHARLOTTESVILLE, VA., US

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20200618 AND 20200624

REG Reference to a national code

Ref country code: BE

Ref legal event code: PD

Owner name: ALLERGAN SALES, LLC; US

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), FUSION; FORMER OWNER NAME: DOGWOOD PHARMACEUTICALS, INC.

Effective date: 20200430

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: ALLERGAN SALES, LLC; US

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE; FORMER OWNER NAME: DOGWOOD PHARMACEUTICALS, INC.

Effective date: 20201026

REG Reference to a national code

Ref country code: FI

Ref legal event code: PCE

Owner name: ALLERGAN SALES, LLC

REG Reference to a national code

Ref country code: HU

Ref legal event code: GB9C

Owner name: ALLERGAN SALES, LLC, US

Free format text: FORMER OWNER(S): DOGWOOD PHARMACEUTICALS, INC., US

Ref country code: HU

Ref legal event code: FH1C

Free format text: FORMER REPRESENTATIVE(S): DR. PETHOE ARPAD, DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

REG Reference to a national code

Ref country code: LU

Ref legal event code: HC

Owner name: ALLERGAN SALES, LLC; US

Free format text: FORMER OWNER: ALLERGAN SALES, INC.

Effective date: 20211118

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: ALLERGAN SALES, LLC

Effective date: 20220203

REG Reference to a national code

Ref country code: AT

Ref legal event code: PC

Ref document number: 734837

Country of ref document: AT

Kind code of ref document: T

Owner name: ALLERGEN SALES, LLC, US

Effective date: 20220118

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230518

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230703

Year of fee payment: 17

Ref country code: CH

Payment date: 20230701

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20240319

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20240514

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240514

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240527

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240509

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240509

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20240528

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240527

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240527

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240509

Year of fee payment: 18

Ref country code: FI

Payment date: 20240528

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20240527

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20240514

Year of fee payment: 18

Ref country code: SE

Payment date: 20240610

Year of fee payment: 18

Ref country code: HU

Payment date: 20240530

Year of fee payment: 18

Ref country code: BE

Payment date: 20240514

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240611

Year of fee payment: 18